This study is not yet accepting patients

A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)

a study on Attention-Deficit/Hyperactivity Disorder

Summary

for people ages 18-70 (full criteria)
at San Francisco, California
study started
estimated completion

Description

Summary

The primary objective of this trial was to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective was to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.

Official Title

A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I

Keywords

Attention-Deficit Hyperactivity Disorder (ADHD) ADHD Hyperkinesis Disease Attention Deficit Disorder with Hyperactivity PDC-1421 Capsule

Eligibility

You can join if…

Open to people ages 18-70

  1. Aged 18-70 years
  2. Female subjects of child-bearing potential must test negative to pregnancy and use appropriate birth control method from the beginning of study to the 15 days later after ending of study
  3. Subjects must be able to understand and willing to sign informed consent
  4. Able to discontinue the use of any psychotropic medications for the treatment of ADHD symptoms at screening
  5. Meet strict operational criteria for adult ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
  6. A total score of 20 or higher on the 18-item total ADHD symptoms score of Conners'

Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Self Report: Short Version (CAARS-S:S) at screening

  1. Have a moderate or severe symptom of ADHD with score of 4 or higher in Clinical Global Impression-ADHD-Severity (CGI-ADHD-S) at screening

You CAN'T join if...

  1. Have any clinically significant concurrent medical condition (endocrine, renal, respiratory, cardiovascular, hematological, immunological, cerebrovascular, neurological, anorexia, obesity or malignancy) that has become unstable and may interfere with the interpretation of safety and efficacy evaluations
  2. Have any clinically significant abnormal laboratory, vital sign, physical examination, or electrocardiogram (ECG) findings at screening that, in the opinion of the investigator, may interfere with the interpretation of safety or efficacy evaluations
  3. Have known serological evidence of human immunodeficiency virus (HIV) antibody
  4. Are pregnant as confirmed by a positive pregnancy test at screening
  5. Have QTc values >450 msec at screening using Fridericia's QTc formula
  6. Have current of bipolar and psychotic disorders
  7. Have a current major depression disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder and eating disorder (also if treated but not currently symptomatic)
  8. Have any history of a significant suicide attempt, or possess a current risk of attempting suicide, in the investigator's opinion, based on clinical interview and responses provided on the Beck Scale for Suicidal Ideation (BSS)
  9. Have a history of jailing or imprisonment in the past 6 months due to worsening of symptoms of ADHD

Location

  • UCSF Medical Center not yet accepting patients
    San Francisco California 94143 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
BioLite, Inc.
ID
NCT02699086
Phase
Phase 2
Study Type
Interventional
Last Updated